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The etiologic agent of chancroid is Haemophilus ducreyi. To fulfill its obligate requirement for heme, H.
ducreyi uses two TonB-dependent receptors: the hemoglobin receptor (HgbA) and a receptor for free heme
(TdhA). Expression of HgbA is necessary for H. ducreyi to survive and initiate disease in a human model of
chancroid. In this study, we used a swine model of H. ducreyi infection to demonstrate that an experimental
HgbA vaccine efficiently prevents chancroid, as determined by several parameters. Histological sections of
immunized animals lacked typical microscopic features of chancroid. All inoculated sites from mock-immu-
nized pigs yielded viable H. ducreyi cells, whereas no viable H. ducreyi cells were recovered from inoculated sites
of HgbA-immunized pigs. Antibodies from sera of HgbA-immunized animals bound to and initiated antibody-
dependent bactericidal activity against homologous H. ducreyi strain 35000HP and heterologous strain CIP542
ATCC; however, an isogenic hgbA mutant of 35000HP was not killed, proving specificity. Anti-HgbA immuno-
globulin G blocked hemoglobin binding to the HgbA receptor, suggesting a novel mechanism of protection
through the limitation of heme/iron acquisition by H. ducreyi. Such a vaccine strategy might be applied to other
bacterial pathogens with strict heme/iron requirements. Taken together, these data suggest continuing the
development of an HgbA subunit vaccine to prevent chancroid.
Genital ulcer diseases (GUDs), including chancroid, are im-
portant risk factors for the heterosexual transmission of the hu-
man immunodeficiency virus (HIV) in certain African and Asian
developing countries. This is especially true early in the course of
HIV epidemics (10, 12, 41, 45, 60). Recent data show that GUDs
can enhance HIV type 1 transmission by 3- to 10-fold (7, 17, 28,
30, 42, 48, 51). The World Health Organization acknowledges
that the prevention of GUDs is an important strategy to control
the spread of HIV infection (39, 40, 67).
Haemophilus ducreyi, a small fastidious gram-negative bac-
terium that infects only humans, is well known for its require-
ment for heme (23, 24, 52, 57, 61). H. ducreyi expresses two
TonB-dependent receptors for heme compounds: the hemo-
globin receptor (HgbA) and the heme receptor (TdhA) (19,
21, 23, 63). During in vitro growth in heme-limiting media,
HgbA is induced to high levels of expression, but TdhA is
induced only at modest levels. In vivo, both receptors are
expressed to some extent, since antibodies are detected after
natural (24) and experimental (14) infections. A role for HgbA
in virulence was established by the inability of an hgbA mutant
of H. ducreyi to initiate human experimental infection, even at a
dose 10 times higher than the infective dose of the parent
strain (3). Since the attenuated hgbA mutant expresses tdhA, it
appears that the ability to acquire/transport heme from hemo-
globin is more efficient than acquisition/transport of heme via
TdhA. It can also be inferred that hemoglobin, as opposed to
free heme, is the most important heme compound during ex-
perimental human infection. However, formal proof has not
yet been obtained, since the tdhA mutant has not been tested
for virulence.
The relative roles of the cellular and humoral arms of the
immune system in resistance to chancroid infection are not well
understood. Chancroid reinfection is common among patients,
suggesting that a nonprotective immune response is generated as
a result of natural infection (8, 25, 33–35, 37). It is well docu-
mented that early in the course of natural or experimental chan-
croid, an intense cellular infiltrate develops locally (27, 58, 59).
This is characterized by an influx of mononuclear cells homing to
affected tissues and perivascular cuffing (37). In untreated human
chancroid, antibodies to H. ducreyi are detected after 3 weeks of
natural infection, and the chancroid lesions resolve in about 6
weeks (11, 38, 50).
In vivo human studies confirm that H. ducreyi is primarily an
extracellular pathogen (5, 6). The paradigm for immunity to
extracellular pathogens is that an antibody response is critical
(32, 47). Two animal models of chancroid infection, the rabbit
model and the swine model, have been used for vaccine stud-
ies, and both are clearance models (14, 31, 49). In these two
models, large infectious doses are required, limited bacterial
multiplication occurs, and the rate of clearance is evaluated. A
number of studies using the rabbit model of chancroid infec-
tion demonstrate that whole cells, crude outer membrane pro-
tein (OMP) preparations, or purified protein vaccines induce
partial immunity to/protection against a challenge with H. du-
creyi strain 35000 (15, 16, 18, 26, 29, 64, 65). None of the
resulting antibodies generated in these studies were shown to
be bactericidal or opsonophagocytic, two common features of
effective vaccines. Recently, using a swine model of chan-
croid, Cole and colleagues demonstrated more rapid clearance
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after repeated infection with H. ducreyi. This resistance could
be passively transferred with immune sera (14). These protec-
tive antibodies were modestly bactericidal and were directed
against a number of OMPs of H. ducreyi.
Two classes of H. ducreyi strains, based on antigenic differ-
ences in a number of OMPs, have been described. In contrast
to the dramatic differences seen between the DsrA and NcaA
proteins from class I and class II strains, HgbA proteins from
the two classes show greater than 95% identity (66). Moreover,
HgbA is expressed on the surface of virulent H. ducreyi cells
and is conserved functionally and structurally. These attributes
suggest that HgbA might be an effective vaccine candidate.
The objective of the present study was to determine the ability
of native HgbA protein to elicit protective immunity in the
swine model of H. ducreyi infection.
MATERIALS AND METHODS
Bacterial strains and culture conditions. The H. ducreyi type strain, 35000HP
(class I strain, human-passaged variant), was obtained from Stanley Spinola,
Indiana University, Indianapolis, IN. H. ducreyi hgbA mutant strain FX504 was
previously described (19, 21), and gmbH mutant 35000.252 (a lipooligosaccharide
[LOS] mutant of parent strain 35000HP whose LOS contains 2-keto-3-deoxy-
octulosonic acid and lipid A only) (4) was obtained from Eric Hansen, University
of Texas Health Science Center, Dallas, TX. CIP542 ATCC (class II strain) was
obtained from the American Type Culture Collection, and C111 (class I strain)
was obtained from William Albritton. DMC 111 (class II strain) was previously
described (66). For routine growth, all strains were maintained at 34.5°C in 5%
CO2 on chocolate agar plates (CAP) containing gonococcal medium base (GCB;
Difco, Detroit, MI), 1% bovine hemoglobin (Becton Dickinson, Sparks, MD),
1% IsoVitaleX (Becton Dickinson, Cockeysville, MD), and 5% fetal bovine
serum (FBS) (Sigma, St. Louis, MO). Except for FX504, all strains were grown
under heme-limiting conditions (GCB with 1% IsoVitaleX and 5% FBS) as
described previously (19). Since the FX504 mutant does not grow under the
described heme-limiting conditions, 5 g of hemin per ml was added to the
above-described broth medium (44).
HgbA purification. HgbA protein was affinity purified as previously described
(19) with the following modifications. Large-scale cultures of H. ducreyi strain
35000HP were grown under heme-limiting conditions in Fernbach flasks con-
taining 1.5 liters of GCB broth with 5% FBS and 1% IsoVitaleX and incubated
overnight at 35°C in the presence of 5% CO2 with shaking. H. ducreyi growth and
the lack of other bacterial or fungal contaminants were confirmed by plating
aliquots of overnight cultures on CAP and GCB agar lacking heme, respectively.
H. ducreyi cells from Fernbach flasks were harvested by centrifugation, and the
pellet was suspended in 15 ml of 10 mM HEPES buffer, pH 8.0, containing 0.6
mg/ml lysozyme. Suspensions were subjected to two cycles of cell disruption in a
French press and then centrifuged at 9,200  g for 20 min. The pellet, containing
broken cells and insoluble cell components, was incubated with 1% N-lauroyl-
sarcosine (#L-5125; Sigma) for 30 min at 37°C with mixing. The sarcosyl-insoluble
fraction, containing primarily outer membrane components, was recovered after
centrifugation at 100,000  g for 1 h and dissolved with 1% Zwittergent 3,14 (Zw)
(Calbiochem) in TEN (20 mM Tris, 150 mM NaCl, 5 mM EDTA, pH 8.0). Zw-
insoluble material was removed by centrifugation at 100,000  g for 1 h. The
Zw-soluble fraction was incubated overnight with hemoglobin-agarose (prepa-
ration described below) at 4°C with gentle mixing to allow binding of HgbA to
the hemoglobin. The next day, the hemoglobin-agarose was poured into a col-
umn and washed with 10 volumes of 0.5% Zw in TEN. The detergent was
exchanged by washing with 1% octylglucoside (OG) in TEN. HgbA was eluted in
1% OG in 200 mM glycine HCl, pH 2.3, and immediately neutralized with 2 M
Tris, pH 8.0. HgbA was concentrated using a Centriprep YM-50 Amicon column
(Millipore, Bedford, MA) and washed with 1% OG in phosphate-buffered saline
(PBS). The protein concentration was determined using a bicinchoninic acid
(BCA) protein assay kit (catalog [cat] #23225; Pierce, Rockford, IL). Aliquots of
purified HgbA were stored frozen at 70°C until needed.
Previously, we used a commercial source of hemoglobin-agarose (cat #H8756,
lot #072k 7082; Sigma) to purify native HgbA, but recent lots did not perform
satisfactorily. Therefore, we prepared hemoglobin affinity supports by covalently
attaching bovine hemoglobin (cat #H2500, lot #010K7618; Sigma) to Affigel 15
(Bio-Rad Laboratories, Hercules, CA) following the manufacturer’s directions.
After preparation, we mock eluted the hemoglobin-agarose using OG-glycine
HCl, pH 2.3, to remove any noncovalently bound hemoglobin that might subse-
quently elute and contaminate our HgbA preparation.
Animals. Yorkshire Cross pigs were obtained at 3 weeks of age and housed at
ambient temperature (20 to 25°C) in AAALAC-accredited biosafety level 2
containment facilities at the North Carolina State University School of Veteri-
nary Medicine. Each pig was kept in an individual enclosure. Pigs received water
and an antibiotic-free high-protein growth ration ad libitum for 6 weeks prior to
immunization and throughout the period of immunization and infection with H.
ducreyi (31). The experimental procedures described herein were reviewed and
approved by the Institutional Animal Care and Use Committees of UNC and
NCSU. For inoculation and biopsy procedures, pigs were sedated with 2 mg of
ketamine HCl (Fort Dodge Laboratories, Fort Dodge, IA) and 2 mg xylazine
(Miles Laboratories, Shawnee Mission, KS) per kg of body weight administered
intramuscularly.
Immunization. Two independent experiments were performed. For each iter-
ation, two pigs were immunized with HgbA and two were mock immunized. The
animals were immunized on day 1 and subsequently received booster immuni-
zations on day 21 and day 42. The immunogen was prepared by adding 500 l
HgbA (0.5 mg/ml) in 0.5% OG to 0.5 ml complete Freund’s adjuvant (cat
#F5881; Sigma) for the initial immunization. For the booster immunizations, 500
l of HgbA (0.5 mg/ml) in 0.5% OG was emulsified in 0.5 ml incomplete
Freund’s adjuvant (cat #F5506; Sigma). The control group of mock-immunized
pigs received injections of the adjuvant and the buffer on the same days. Each
immunization was performed in two intramuscular injections on opposite sides of
the nuchal region.
Sera. Serum samples were obtained immediately before each immunization,
before challenge and one week after challenge. Hereafter, we will refer to sera
obtained prior to the first immunization and those obtained after three immu-
nizations as “preimmunized” and “postimmunized” sera, respectively. Individual
or pooled sera from HgbA-immunized or mock-immunized animals were heat
inactivated at 56°C for 45 min and filter sterilized for biological assays. Normal
pig serum was obtained from unimmunized pigs. All samples were aliquoted and
stored frozen at 80°C. Human serum was obtained by informed consent from
four individuals without histories of chancroid. Sera were pooled, aliquoted, and
stored at 80°C until use. Freezing and thawing of samples were kept to a
minimum. Immunoglobulin G (IgG) was purified on protein G columns (Pierce,
Rockford, IL) following the manufacturer’s instructions.
Inoculum and infection. To challenge after immunization, we followed the
published procedure for inoculation of swine (31), with the exception that the H.
ducreyi cells were suspended in GCB instead of PBS. We used Multi-Test ap-
plicators (Lincoln Diagnostics, Decatur, IL), which deliver approximately 5 
104 CFU of H. ducreyi (14, 54), to inoculate animals. In the first iteration of this
experiment, swine were challenged on 16 sites on the dorsum of the right ear with
a suspension containing 5  104 CFU of H. ducreyi and on 16 sites on the left ear
with a suspension containing 10-fold fewer H. ducreyi cells (5  103 CFU). In the
second iteration, only 5  104 CFU was used for inoculation at 16 sites on the
right ear of each pig. Viability of the inocula was monitored prior to and after
each experiment; there was no decrease in CFU detected. All animals were
visually observed at 2, 5, and 7 days after inoculation.
Biopsy samples. One week after challenge with H. ducreyi, biopsy samples were
taken from pig ears by using a 6-mm-diameter skin punch extractor (Acuderm,
Lauderdale, FL). Each sample was bisected into 2 equal parts. One section was
minced and cultured on CAP containing 3 g/ml vancomycin. H. ducreyi colonies
were identified by typical buff-yellow to gray colonial coloration and by their char-
acteristic property of remaining intact when pushed across the agar surface. Gram
stains confirmed bacteria as small pleomorphic gram-negative rods.
Statistical analysis was performed only with data from biopsy samples from
animals for which the standard challenge dose of 5  104 CFU of H. ducreyi was
used. To assess the effectiveness of the vaccine, we first determined the mean
colony count from each pig. Because we anticipated that the mean colony counts
would not be normally distributed, we used a Wilcoxon rank sum test to compare
the two groups of pigs. With this approach, the multiple biopsy samples from
each pig increase the precision of the estimates of the colony counts within each
pig, but the comparison is based on the pig as the unit of analysis. Identical
results were obtained using the median colony counts for each pig.
The second half of the biopsy sample was fixed in 4% paraformaldehyde in
PBS and embedded in paraffin. Twelve sections were made from each biopsy
sample and stained with hematoxylin-eosin (H&E) for histologic analysis. Slides
were coded and graded blindly on a scale from 1 to 5. This numerical scoring
system was used to describe the stages of ulcer development as previously
described (54). Briefly, skin of normal appearance was assigned a score of 1; the
presence of perivascular and interstitial mononuclear cell infiltrate was assigned
a score of 2; the presence of an intraepidermal pustule with neutrophils and
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necrotic debris was assigned a score of 3; an epidermal pustule accompanied by
keratinocyte cytopathology and diffuse mononuclear and polymorphonuclear
dermal infiltrate was scored as 4; and ulceration or dermal erosion accompanied
by confluence of immune cells was scored as 5 (54). An ECLIPSE E800 (Nikon
Co., Tokyo, Japan) microscope and QCapture software 1394 (Quantitative Im-
aging Co., Burnaby, BC, Canada) were used to make high-performance digital
images of H&E-stained sections.
Bactericidal assay. All strains used in this study are resistant to 50% normal
human serum (NHS). The bactericidal activity of pig serum against the indicated
H. ducreyi strains was determined by use of an immune bactericidal assay as
previously described (1, 20, 22). Briefly, H. ducreyi cells were grown in GCB broth
under heme-limiting conditions to induce expression of HgbA. The bacteria were
harvested by centrifugation, and cell density was adjusted to an optical density at
600 nm (OD600) of 0.2 in GCB without supplements. After a 104-to-105 dilution,
65 l (approximately 100 to 300 CFU of viable H. ducreyi cells) was placed in the
wells of a sterile 96-well plate (Falcon microtest tissue culture plate; Becton
Dickinson, Franklin Lakes, NJ). Ten l of preimmunized and postimmunized pig
sera or GCB was separately added to the H. ducreyi cells and incubated for 30
min at 35°C to allow antibody binding. Twenty-five l of NHS (the source of
complement) was added to equal a total volume of 100 l to allow complement
activation, deposition, and bacterial killing. After 45 additional minutes, 80 l
was plated on CAP; colonies were counted after 48 h of incubation. The percent
survival of bacteria was determined by dividing the number of colonies that
survived in fresh complement by the number of colonies surviving in heat-
inactivated NHS and multiplying by 100. Normal pig serum was also used as a
source of complement in the bactericidal assay; since no significant difference in
activity was noted, only the data obtained with human complement are pre-
sented. Neisseria gonorrhoeae strain F62 (55) or H. ducreyi dsrA mutant FX517
(22) was used as a positive control for NHS bactericidal activity. To ensure that
killing activity was due to antibody and complement and that these antibodies
were directed against HgbA, a number of controls were performed. First, H.
ducreyi cells were incubated in fresh or heated complement source in the absence
or presence of immune serum. Killing was observed only when both fresh com-
plement and postimmunized pig serum or IgG were present. Second, the spec-
ificity of the bactericidal activity was assessed by use of the H. ducreyi hgbA
mutant FX504 and gmbH 35000.252 (a LOS mutant) (4) as the target bacte-
ria. Bactericidal data were compared with a paired t test, using Excel (Mi-
crosoft) software. A P value of 0.05 was accepted as the level of statistical
significance.
ELISA. An enzyme-linked immunosorbent assay (ELISA) for detection of
anti-HgbA antibodies from pig sera was performed in 96-well plates (Falcon Pro
Bind, cat #3915; Becton Dickinson, Franklin Lakes, NJ). Plates were coated with
HgbA (200 ng/well) in 0.1 M carbonate buffer, pH 9.4, overnight at 4°C. Residual
binding sites were blocked with 2% bovine serum albumin (BSA) (Roche Diag-
nostics Co., Indianapolis, IN) in PBS with 0.01% azide (PBS/A) for 1 h at room
temperature (RT). Serial fivefold dilutions of pig sera were prepared using 1%
BSA in PBS. The final dilution of serum samples tested was 1:3  106. Each
dilution was added (100 l/well) to the coated/blocked ELISA plates and incu-
bated at RT for 1 h. After washing three times with 0.05% (vol/vol) Tween 20 in
PBS (PBS/T wash buffer), alkaline phosphatase-conjugated rabbit anti-pig IgG
(cat #A1192; Sigma-Aldrich Inc., St. Louis, MO) diluted 1:10,000 (vol/vol) in
PBS/T was added. Plates were incubated at RT for 1 h and washed five times with
wash buffer. Color development was achieved by adding 50 l/well of 1-Step
p-nitrophenyl phosphate substrate (Pierce, Rockford, IL). The plates were incu-
bated for 15 min at RT, and the reaction was stopped by the addition of 50 l 2
M NaOH. Optical density was measured at 405 nm on a 1420 VICTOR2 mul-
tilabel counter (Wallac Oy, Turku, Finland). The positive-control serum was
rabbit anti-recombinant HgbA and the secondary antibody for this was goat
anti-rabbit alkaline phosphatase (1:10,000). This serum was obtained by immu-
nizing a New Zealand White rabbit three times with 200 g of recombinant
HgbA (rHgbA) (66). The first immunization used complete Freund’s adjuvant
and the second two immunizations used incomplete Freund’s adjuvant. Speci-
ficity of the anti-rHgbA serum was shown in Western blots against 35000 and
hgbA mutant FX504 (data not shown). The negative-control serum was rabbit
anti-recombinant DsrA serum (13). The background was determined as the mean
OD405 of wells not containing primary antibodies. The endpoint titer of antibodies
was defined as the reciprocal of the highest serum dilution that gave a reading above
an OD405 of 0.1 as previously described (9). Each sample was run in duplicate on at
least three different days. The ability of anti-HgbA IgG to block hemoglobin binding
to HgbA was evaluated with an ELISA format similar to that of the direct ELISA.
After immobilization of HgbA, blocking, and washing, purified pig IgG (0.2 mg/ml
in a volume of 100 l) or sera (1:10) were added to each well, and incubation of the
wells for 20 min at RT was followed by three washes with wash buffer. Human
digoxigenin-labeled hemoglobin (1:100) was added to the wells, and the wells were
incubated at RT for 1 h. After three washes with wash buffer, alkaline phosphatase-
conjugated antidigoxigenin antibodies (cat #11327720; Roche Diagnostic, Indianap-
olis, IN) were added at a dilution of 1:5,000 (vol/vol) in PBS, and the wells were
incubated for 1 h at RT. Color development was achieved as described above.
Human hemoglobin was labeled according to the manufacturer’s instructions (DIG
protein labeling kit; Roche Diagnostic).
Western blots. Total cellular proteins of H. ducreyi strains (approximately 0.5 
107 CFU per lane) were separated by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) under reducing conditions. Proteins were trans-
ferred to nitrocellulose membranes and subjected to Western blotting as previ-
ously described (1). Blots were probed with individual or pooled pig sera diluted
1:10,000. The secondary rabbit anti-pig IgG alkaline phosphatase-conjugated
antibodies (cat #A1192; Sigma) were diluted 1:15,000. Binding of secondary
antibodies was detected using Lumi-Phos chemiluminescent substrate (Pierce,
Rockford, IL). To test for the presence of contaminating LOS in purified HgbA
immunogen preparations, the HgbA was digested with proteinase K and sub-
jected to Western blotting using anti-LOS monoclonal antibodies (MAbs)
MAHD6 (LOS epitope, DD-Hepp-136--D-Glcp) and MAHD7 (epitope is the
common conserved inner core region of the LOS) (2) and wheat germ agglutinin-
horseradish peroxidase (HRP). The secondary antibody was goat anti-mouse
alkaline phosphatase (cat #A5153; Sigma). Known amounts of phenol-water
purified LOS were used as standards for comparison (36).
Immunoglobulin G binding to whole H. ducreyi cells. Ten l of diluted pig sera
(1:50 in GCB, 1:500 final dilution) was incubated with a 90-l suspension of H.
ducreyi strains 35000HP, FX504, and CIP542 ATCC (OD600  0.4, approxi-
mately 5  107 CFU) or with 90 l GCB in a MultiScreen filter plate (Millipore
Corp., Bedford, MA) for 30 min. The plates were then suctioned and washed
three times with GCB. Anti-pig IgG-HRP (cat #A7042; Sigma-Aldrich Inc., St.
Louis, MO) was added and incubated for 30 min at RT; this was followed by
suctioning and five washes. HRP substrate (ECL; Amersham Bioscience Corp.,
Piscataway, NJ) was added and chemiluminescence was detected by a 1420
VICTOR2 multilabel counter (Wallac Oy, Turku, Finland). To ensure equal
loading of class I H. ducreyi strains, we used an anti-rDsrA pig serum as an
internal control. The antisera to DsrA were prepared by immunization of pigs
using the same purified recombinant DsrA immunogen we previously described
(13). Recombinant DsrA was mixed with Ribi adjuvant, and 500 g was injected
intramuscularly in the nuchal region. The two immunizations were separated by
3 weeks.
FIG. 1. Purification of HgbA. Various fractions from hemoglobin-
agarose affinity purification of HgbA are shown in this Coomassie
blue-stained 15% SDS-PAGE gel. Lanes: kDa, kilodalton (molecular
marker lane); SM, French-pressed cell starting material; SI, sarcosyl-
insoluble fraction; Zw Sol, Zwittergent 3,14-soluble fraction applied to
a hemoglobin-agarose column; Zw Ins, Zwittergent 3,14-insoluble
fraction; UB, unbound flowthrough fraction not bound to hemoglobin-
agarose; HgbA (15 g by BCA total protein determination); BSA Stds,
purified bovine serum albumin used to semiquantitate intact HgbA
protein. The purified HgbA shown here was the immunogen for the
first vaccine experiment. Similar results were obtained in a second
purification, which was used for the second vaccine iteration (not
shown).
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RESULTS
Purification of HgbA. We purified HgbA from type strain
35000HP using hemoglobin-agarose affinity chromatography
as detailed in Materials and Methods. HgbA was 95% pure
as judged by Coomassie blue staining of 15% SDS-PAGE gels
(Fig. 1). Two minor additional bands of approximately 45 kDa
and 20 kDa were also observed. The 45-kDa band reacted with
independently derived anti-rHgbA rabbit sera. Moreover, an
identically sized immunoreactive band is seen in whole-cell
lysates of 35000 but not of FX504 (data not shown). Thus, this
band may represent a breakdown product of HgbA. The 20-
kDa protein band was not recognized by any HgbA antibodies,
and the identity of this band is not presently known. We ana-
lyzed proteinase K-digested purified HgbA protein prepara-
tions in Western blots for the presence of contaminating LOS
by use of anti-LOS MAbs and wheat germ agglutinin lectin.
Comparison of the signal obtained with proteinase K-digested
purified HgbA with the signals obtained with purified LOS
standards indicated that less than 5 ng of LOS was present per
g of purified HgbA (data not shown). The concentration of
total protein was measured by BCA, and the concentration of
intact HgbA was estimated by comparing the staining intensity
to BSA standards (Fig. 1).
Effect of HgbA immunization on the development of lesions
in swine. In two separate experiments, four pigs were thrice
immunized with the HgbA vaccine while four pigs were immu-
nized with mock vaccine, each in Freund’s adjuvant (see Ma-
terials and Methods for details). Three weeks after the third
immunization, the dorsal skin of pig ears was inoculated with
viable H. ducreyi strain 35000HP using an allergy-testing de-
vice. Each site was inoculated with approximately 5  104 CFU
of H. ducreyi 35000HP. In the first experiment only, pigs from
each group were also inoculated with 10-fold fewer CFU of H.
ducreyi to examine the effect of a lowered dose on the devel-
opment of lesions. The sites of infection were observed 2 and
7 days after inoculation. By day 2, papule-like lesions had
developed on both HgbA-immunized and mock-immunized
pig groups. On day 7, lesions from HgbA-immunized pigs ap-
peared smaller on a macroscopic level. While macroscopic
observations varied somewhat within each group, as a whole,
lesions on immunized animals appeared smaller and less ery-
thematous than those from mock-immunized animals.
Histopathology of skin lesions. The biopsy samples of le-
sions were sectioned, H&E stained, and analyzed microscopi-
cally by two independent, blinded observers. Representative
sections are shown in Fig. 2. In general, sections from HgbA-
immunized animals contained relatively mild inflammatory in-
filtrates and an intact basal lamina at the epidermal-dermal
junction. Additionally, minor localized dermal perivascular
and interstitial mononuclear cell infiltrate was observed. In
contrast, sections from mock-immunized control pigs exhibited
extensive thickening of the epidermis, intraepidermal pustule
formation with diffuse hyperplasia, and acanthosis of epithelial
cells. Sections from mock-immunized pigs showed a com-
pletely disorganized basal membrane layer. The relative sever-
ity of each lesion was graded and subjected to statistical anal-
ysis as previously described (54). The average histology score
for lesions obtained from HgbA-immunized pigs was 2.0, while
the score was 3.4 for mock-immunized pigs (P  0.035, paired
t test). Thus, immunization with HgbA reduced initial size and
severity of lesion formation and/or increased the speed of
healing.
Recovery of H. ducreyi. Seven days after challenge with live
35000HP cells, we recovered viable H. ducreyi cells from 17
FIG. 2. Microscopic examination of lesions. Hematoxylin-eosin staining of skin biopsy sections of pigs 1 week after challenge with live H. ducreyi
35000HP cells. (A) Image of normal pig skin; (B and C) skin cross-sections from HgbA-immunized pigs; (D through F) skin sections of
mock-immunized pigs. Magnification values are shown.
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biopsy samples cultured from the four mock-immunized pigs.
Strikingly, none of the biopsy samples (n  20) from the four
HgbA-immunized pigs yielded viable H. ducreyi cells (Table 1)
(P  0.0139, Wilcoxon rank sum). The numbers of H. ducreyi
cells recovered from lesions of mock-immunized pigs varied
considerably. In the mock-immunized group, an effect of chal-
lenge dose was observed; recovery was 19.1-fold higher from
lesions inoculated with 5  104 CFU than from lesions inoc-
ulated with 5  103 CFU (data not shown). Therefore, HgbA
immunization prevented the recovery of H. ducreyi.
Antibody response to HgbA. The antibody response to HgbA
was monitored using ELISA, whole-cell binding, and Western
blot assays. ELISA data (Fig. 3) indicated that all pigs were
free of anti-HgbA antibodies before immunizations and that
the levels of anti-HgbA IgG increased only in the sera of
HgbA-immunized groups. After three immunizations with
HgbA antigen, reciprocal endpoint titers of anti-HgbA anti-
bodies in individual sera of HgbA-immunized animals varied
from 5  105 to 3  107. All sera from mock-immunized
animals had endpoint titers of less than 5  102. These data
indicate that HgbA is a highly immunogenic protein.
In order to be protective, antibodies should bind to the
surface of intact bacteria. To measure antibody binding to
whole H. ducreyi cells, sera were mixed with H. ducreyi cells and
antibody binding was assessed. Significant antibody reactivity
with the surface of H. ducreyi 35000HP cells was observed only
with postimmunized pig sera from HgbA-immunized swine
(Fig. 4). To assess the cross-reactivity of antibodies elicited to
the class I HgbA from H. ducreyi strain 35000HP, we measured
binding to heterologous class II strain CIP542 ATCC. Anti-
HgbA class I antibodies bound class II strain CIP542 ATCC
almost as well as they bound strain 35000HP. As expected, H.
ducreyi hgbA mutant FX504 was only weakly recognized with
IgG from HgbA-immunized pig sera. This indicated that anti-
TABLE 1. H. ducreyi recovery from pig ear biopsy samples
Experiment
no.
Mock immunization data HgbA immunization data
Pig no. No. of biopsy samples Bacterial recovery[median CFUa (range)] Pig no. No. of biopsy samples
Bacterial recovery
[median CFU (range)]
1 1 4 5.0 (3, 10) 5 4 0 (0, 0)
2 4 160.5 (138, 269) 6 4 0 (0, 0)
2 3 3 400.0 (41, 600) 7 6 0 (0, 0)
4 6 11.5 (2, 37) 8 6 0 (0, 0)
Total 17 26.0 (2, 600) 20 0 (0, 0)b
a CFU per biopsy sample half.
b P  0.0139 compared to mock immunization data by Wilcoxon rank sum test comparing bacterial recovery. P  0.029 by Fisher’s exact test comparing the number
of infected pigs.
FIG. 3. ELISA. Profiles of specific IgG responses of individual pig
sera diluted 1:5,000. The sera from four HgbA-immunized and four
mock-immunized pigs were collected at immunization 0 (preimmuni-
zation) and 1, 2, and 3 (3 weeks after immunizations 1, 2, and 3,
respectively). Sera were tested for IgG reactivity against immobilized
HgbA. Bound IgG was detected with alkaline phosphatase-labeled
anti-pig IgG. Each sample was run in duplicate on at least three
different days. The results were expressed as units of optical density
(OD) at 405 nm and represent the mean 	 standard deviation (SD).
FIG. 4. Binding of anti-HgbA to whole H. ducreyi cells. A dilution
containing 0.2 l of each preimmunized (Pre) or postimmunized
(Post) HgbA serum was mixed with 2  107 CFU of the indicated H.
ducreyi strains in a total volume of 100 l (final dilution of serum,
1:500). After binding for 30 min, bacteria were suctioned and washed
and antibody binding was detected with a secondary HRP-conjugated
anti-pig IgG antibody followed by chemiluminescence detection. The
control anti-DsrA serum was made in a pig by using recombinant DsrA
from strain 35000. The serum from each pig was individually tested for
binding to whole cells in three separate experiments. The data were
combined for each group (HgbA or mock immunized) and expressed
as the mean 	 SD. There was no significant binding of pre- or postim-
munized sera from mock-immunized pigs to whole cells (data not
shown). RLU/sec, relative light units/s.
2228 AFONINA ET AL. INFECT. IMMUN.
bodies elicited to HgbA recognized primarily HgbA on the
surface of 35000HP cells and not other surface-exposed anti-
gens. Furthermore, IgG from sera of mock-immunized pigs did
not show any significant binding with exposed bacterial anti-
gens and resembled the preimmunized pig IgG (Fig. 4). Thus,
antibodies elicited to HgbA were highly specific and bound to
surface-exposed epitopes of HgbA.
To determine the specificity of the anti-HgbA IgG antibody,
we subjected total cellular proteins to Western blotting under
denaturing conditions. When probed with the anti-HgbA IgG,
HgbA was recognized only weakly (data not shown). Binding
to a molecule of approximately 20 kDa was also observed. This
20-kDa band was not LOS, since no signal was obtained when
H. ducreyi cellular proteins were first treated with proteinase K
prior to loading in Western blots (data not shown).
Bactericidal activity of sera and purified IgG from HgbA-
immunized pigs. Bactericidal activity is commonly used as an in
vitro correlate of protection in assessing the efficacy of gram-
negative vaccines. Therefore, we tested the ability of HgbA-im-
munized pig serum to kill cells of virulent strain 35000HP. We
observed more than 50% bacterial killing in 10% pooled sera
from animals immunized with HgbA (Fig. 5). Little or no killing
was observed in the preimmunized or mock-immunized pig sera.
Killing required active complement, since heating the comple-
ment abrogated the killing effect. Moreover, purified IgG (final
concentration, 0.5 mg/ml) from HgbA-immunized pigs killed as
well as whole serum (Fig. 5). To examine whether the HgbA-
immunized pig serum was bactericidal against other H. ducreyi
strains, we tested heterologous strains in the bactericidal assay by
use of pooled HgbA-immunized pig sera. Postimmunized pig sera
killed heterologous strains C111 (class I), CIP542 ATCC (class
II), and DMC 111 (class II) at modest levels (Fig. 5). Individual
pig sera were also tested for bactericidal activity against strain
35000HP, and the survival varied between 30 and 70% (data not
shown). Neither pooled pig sera (Fig. 5) nor individual sera killed
the isogenic hgbA mutant FX504. Interestingly, killing of H.
ducreyi 35000HP was similar to that of the deep rough LOS
mutant 35000.252, consistent with anti-HgbA antibodies being
FIG. 5. Bactericidal killing of H. ducreyi. Survival of H. ducreyi in pooled pig serum in the presence of 25% NHS complement. Target strains
are shown on the left. Purified pig IgG was used at 5% concentration relative to normal pig IgG serum levels (final concentration, 0.5 mg/ml). The
data are compiled from separate experiments done on at least three different days and represented as the mean 	 SD. Statistical difference
(P value) was obtained by Student’s paired t test.
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responsible for killing as opposed to anti-LOS antibodies.
Taken together, these data suggest that the modest bactericidal
effect observed was due to anti-HgbA antibodies.
Effect of anti-HgbA IgG on hemoglobin binding. We previ-
ously demonstrated that the hgbA mutant FX504 is highly atten-
uated in the human experimental model of chancroid (3). This
attenuation is thought to be attributed to its inability to bind
hemoglobin and obtain heme for growth. This observation
prompted us to examine the anti-HgbA pig antibodies to block
hemoglobin binding to HgbA. In an ELISA format, immobilized
HgbA was incubated with pre- or postimmunized pig serum; this
was followed by binding of labeled human hemoglobin. Incuba-
tion of postimmunized anti-HgbA IgG with immobilized HgbA
receptor inhibited subsequent hemoglobin binding, whereas little
or no effect was seen with preimmune or irrelevant IgGs (Fig. 6).
DISCUSSION
A swine model of H. ducreyi infection was used in the present
vaccine study because available evidence suggests that the histo-
pathology of the lesions of the swine model closely resembles that
of human chancroid (31) and that the swine immunology and skin
structure closely resemble their human counterparts (53). Re-
cently, it was shown that repeated infection with H. ducreyi in pigs
elicited a form of immunity, since after the second and third
challenges, lesions resolved more quickly and became sterile
more rapidly than after a single challenge (14). Although the
immune sera from thrice-infected pigs recognized a number of
antigens, including HgbA, it was not clear which antigens might
be responsible for the immunity or bactericidal activity of these
sera. However, the immunity could be passively transferred, prov-
ing that the antibody-mediated protection in the swine model of
infection is important (14).
In the present study, we demonstrate that HgbA may be an
important vaccinogen. Immunization with native HgbA re-
sulted in (i) reduced macroscopic and microscopic lesion de-
velopment after H. ducreyi challenge, (ii) the absence of viable
H. ducreyi cells in day 7 biopsies, (iii) the production of a
vigorous antibody response, (iv) antibodies that bound intact
bacteria, and (v) the development of bactericidal antibodies
and antibodies that inhibited hemoglobin binding to HgbA.
Macroscopic and microscopic examination of lesions was
consistent with a protective effect by HgbA. Microscopically,
biopsy samples from lesions of HgbA-immunized animals re-
sembled those of normal skin sections compared to biopsy
samples from mock-immunized animals.
Perhaps the most important finding from this study is that
HgbA completely prevented recovery of H. ducreyi. In contrast,
mock immunization did not prevent recovery of H. ducreyi, and
all cultured biopsy samples yielded organisms. In the first iter-
ation, in addition to the standard inoculum, a 10-fold-lower
inoculum level was also used. H. ducreyi cells were recovered
from all lower-inoculum-level lesions of mock-immunized an-
imals but not from HgbA-immunized animals. Thus, it appears
that the HgbA vaccine protected against a challenge 10-fold
higher than that required for initiating disease in the mock-
immunized group.
Immunization with purified HgbA elicited antibodies that
bound native HgbA in the context of the outer membrane of H.
ducreyi cells. These antibodies bound poorly to the hgbA mu-
tant, demonstrating specificity for HgbA. In Western blots,
HgbA was weakly recognized with HgbA-immunized pig sera,
probably due to its change in conformation after denaturation
or poor transfer from the gel to nitrocellulose. Previously, we
found that mouse monoclonal antibodies (44) and rabbit an-
tisera (36) elicited to native HgbA also failed to bind in West-
ern blots, suggesting that the conformation of HgbA is com-
plex and critical to antibody binding. In Western blots, we also
found that anti-HgbA sera recognized an unknown component
of approximately 20 kDa. This reactivity is probably not to
LOS, because this 20-kDa molecule was also present in the
35000.252 los mutant and reactivity was proteinase K sensitive.
In studies not presented here, this molecule seemed to frac-
tionate in the cytosolic fraction (data not shown). Further-
more, the 20-kDa antigen cannot account for the bactericidal
activity we observed, since this molecule is present in hgbA
strain FX504, which was not killed in bactericidal assays (data
not shown). Moreover, LOS gmbH mutant 35000.252 shows a
survival rate in 10% immune pig serum which is similar to that
of H. ducreyi 35000HP, confirming the specificity of immunized
pig antibodies to HgbA.
The mechanism of protection of the HgbA vaccine is presently
not known. We found modest evidence of bactericidal killing of
homologous strain 35000HP, initiated by anti-HgbA sera or IgG.
Moderate bactericidal killing was also observed in heterologous
H. ducreyi strains C111 (class I), DMC 111 (class II), and CIP542
ATCC (class II). Thus, since the HgbA deduced protein se-
quences are more than 95% identical (66) and if anti-HgbA
antibodies are important, it is conceivable that a monovalent
HgbA vaccine could protect against a wide variety of H. ducreyi
strains.
An important part of mammalian innate immune systems is
based on the concept of “nutritional immunity” (32, 43, 46, 56,
62). Mammals prevent growth of microbes by utilizing various
proteins that bind and sequester heme and iron necessary for
bacterial growth (23, 46). Obligate human bacterial pathogens
FIG. 6. Inhibition of hemoglobin (Hgb) binding by HgbA-immu-
nized pig serum or pig IgG. Purified HgbA was coated onto ELISA
plates, the plates were blocked, and the abilities of various antibodies
to HgbA to block labeled hemoglobin binding to the receptor were
tested. Pre, preimmune; Post, postimmune; Pig IgG, purified pig IgG;
anti-rHgbA, rabbit anti-recombinant HgbA (positive control); anti-
DsrA I, rabbit anti-recombinant DsrA (negative control). The data are
compiled from separate experiments done on at least three different
days.
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have evolved ingenious strategies to overcome these heme/
iron-withholding systems. For example, gram-negative bacteria
have evolved TonB-dependent receptors for heme, hemoglo-
bin, transferrin, and lactoferrin that enable them to bind and
utilize the heme/iron present in these proteins. We found that
anti-HgbA IgG blocked hemoglobin binding to HgbA, suggest-
ing that it is possible to induce antibodies that can block heme/
iron acquisition. Thus, the protection observed in this study
perhaps may be partly or wholly due to inhibition of bacterial
growth by induced nutritional immunity.
The role of cellular immunity was not examined in this study.
The possibility exists that the immunity we observed is due to
a cellular response. Further studies are needed in this area.
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